Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of TQ Formula in Treating Participants Who Have Tested Positive for Novel Coronavirus 2019 (BOSS-Covid-19)

NCT04914377 is registered in ClinicalTrials.gov with Novatek Pharmaceuticals as lead sponsor.

NCT NCT04914377
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04914377 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of TQ Formula in Treating Participants Who Have Tested Positive for Novel Coronavirus 2019 (BOSS-Covid-19)
Lead sponsor
Novatek Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
June 8, 2021
Completion date
January 1, 2022
Enrollment
55 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

covid19